Trends in Pharmacological Sciences

Article	Citations
Subscription and Copyright Information	761
Subscription and Copyright Information	490
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	327
Subscription and Copyright Information	199
Subscription and Copyright Information	177
Advisory Board and Contents	177
Subscription and Copyright Information	172
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	160
Peptides as a therapeutic strategy against Klebsiella pneumoniae	151
Muscarinic receptors: from clinic to bench to clinic	144
Shearing of surface mucin saps tumor cell strength	139
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	123
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	117
Structural asymmetry in FGF23 signaling	116
Compstatins: the dawn of clinical C3-targeted complement inhibition	110
Structural pharmacology and mechanisms of GLP-1R signaling	104
Targeting complement in neurodegeneration: challenges, risks, and strategies	104
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	102
Therapeutic inhibition of ferroptosis in neurodegenerative disease	97
Direct in vivo CAR T cell engineering	93
Advisory Board and Contents	90
Advisory Board and Contents	89
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	84
Phenotypic approaches for CNS drugs	83
A smart hospital-driven approach to precision pharmacovigilance	83

Nemolizumab (Nemluvio®) for prurigo nodularis	75
Emerging strategies for beta cell transplantation to treat diabetes	75
HSV-1 as a gene delivery platform for cancer gene therapy	74
Advisory Board and Contents	73
A deep dive into degrader-induced protein-protein interfaces	72
Optogenetic engineering for precision cancer immunotherapy	66
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	65
Ribosome-directed cancer therapies: the tip of the iceberg?	64
Leveraging human microbiomes for disease prediction and treatment	64
A perspective on psychedelic teratogenicity: the utility of zebrafish models	64
Engineering ACE2 decoy receptors to combat viral escapability	63
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	62
Genetically engineered loaded extracellular vesicles for drug delivery	60
siRNA drug Leqvio (inclisiran) to lower cholesterol	60
Advisory Board and Contents	59
Advancing non-destructive analysis of 3D printed medicines	59
Suzetrigine for moderate to severe acute pain	59
The structure, function, and pharmacology of MRGPRs	58
Close to a year in TIPS’ saddle – I am optimistic	57
Subscription and Copyright Information	56
Thriving as members of under-represented groups in pharmacology-related careers	54
Lipoxygenases in chronic liver diseases: current insights and future perspectives	51
Mentoring future science leaders to thrive	50
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	50
Emerging approaches to induce immune tolerance to therapeutic proteins	49
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	49
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	47
Could dexmedetomidine be repurposed as a glymphatic enhancer?	47
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	47
The promise of targeted protein degradation approaches	46
Advisory Board and Contents	46
Piezo1: structural pharmacology and mechanotransduction mechanisms	46
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	42
The road less traveled: activating an oncogenic kinase	42
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	41
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	41
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	40
Subscription and Copyright Information	40
Salt-inducible kinases: new players in pulmonary arterial hypertension?	40
Promising neuroimmune targets and drugs for CNS diseases	40
Advisory Board and Contents	39
A novel function of the M2 muscarinic receptor	39
Nanocarriers for oral delivery of biologics: small carriers for big payloads	38
BTK inhibitors: past, present, and future	38
The end of the beginning in understanding SLC22 polyspecificity	38
Monkeypox: potential vaccine development strategies	37
Protein acylations in cancer immunity: effects and therapeutic opportunities	36
Frizzleds act as dynamic pharmacological entities	36
Targeting intracellular protein–protein interactions with macrocyclic peptides	35
Validation of agent-based models of surface receptor oligomerisation	35

Decoding pseudouridine: an emerging target for therapeutic development	35
Advisory Board and Contents	34
Metabolic regulation in normal and leukemic stem cells	33
GPR35: from enigma to therapeutic target	32
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	32
Circulating tumor cells in precision medicine: challenges and opportunities	32
Demographic diversity in platelet function and response to antiplatelet therapy	32
Eflornithine for treatment of high-risk neuroblastoma	30
Engineered antibody fusion proteins for targeted disease therapy	30
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	30
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	29
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	29
Recent advances in generative biology for biotherapeutic discovery	29
Development of PROTACs using computational approaches	29
Subscription and Copyright Information	28
Subscription and Copyright Information	28
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	28
A novel anticancer pharmacological agent targeting mitochondrial complex I	27
Biochemical perspectives on targeting KMT2 methyltransferases in cancer	27
Intra- and intercellular signaling pathways associated with drug-induced cardiac pathophysiology	27
Subscription and Copyright Information	27
Tackling chronic kidney disease in diabetic patients with finerenone	27
Targeting sensory neuron GPCRs for peripheral neuropathic pain	26
Harnessing associative learning paradigms to optimize drug treatment	26
Boosting CAR-T cell therapy through vaccine synergy	26
Targeting plasma membrane cholesterol as a novel anticancer therapy	26
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	25
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	25
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	25
Biologics and cardiac disease: challenges and opportunities	25
High-power screening (HPS) empowered by DNA-encoded libraries	25
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	24
Visceral obesity and HFpEF: targets and therapeutic opportunities	24
Recent advancements in vaccine research and development	24
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	24
Subscription and Copyright Information	24
Neutrophil extracellular traps in wound healing	24
Taming PRMT5–adaptor protein interactions	23
Challenges and opportunities associated with rare-variant pharmacogenomics	23
Teaching an old dog new tricks: repurposing β-lactams	23
GABAA receptors as targets for treating affective and cognitive symptoms of depression	22
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	22
Circadian biology to advance therapeutics for mood disorders	22
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	21
Advisory Board and Contents	21
NLRP3 and pyroptosis blockers for treating inflammatory diseases	21
Potential for targeting small heat shock protein modifications	21
Odorant receptors as potential drug targets	20
Glymphatic-stagnated edema induced by traumatic brain injury	20
Subscription and Copyright Information	20
GPCR-dependent and -independent arrestin signaling	20
The structure and function of YTHDF epitranscriptomic m6A readers	19
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	19
Membrane protein production and formulation for drug discovery	19
Targeted protein degrader development for cancer: advances, challenges, and opportunities	19
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	18
Hans Jürg Schatzmann (1924–2021)	18
Bridging the gap in neuropsychiatric translational research	18
Advisory Board and Contents	18
Structural perspective of class B1 GPCR signaling	18
Advisory Board and Contents	18
Thapsigargin: key to new host-directed coronavirus antivirals?	17
Harnessing deep learning for enhanced ligand docking	17
Advancing small-molecule drug discovery by encoded dual-display technologies	17
Subscription and Copyright Information	17
NET-targeted therapy: effects, limitations, and potential strategies to enhance treatment efficacy	17
Screening strategies for identifying RNA- and ribonucleoprotein-targeted compounds	16
Learning from natural design for local anesthetic delivery	16
Glaucoma: neuroprotection with NAD-based therapeutic interventions	16
Malolactone strikes: K-Ras-G12D's Achilles' heel	16
Leveraging non-enzymatic functions of LSD1 for novel therapeutics	16
Electroceuticals: emerging applications beyond the nervous system and excitable tissues	16
Mitochondrial dynamics proteins as emerging drug targets	15
Celiac disease: mechanisms and emerging therapeutics	15
Emerging epigenetic insights into aging mechanisms and interventions	15
Advisory Board and Contents	15
Advisory Board and Contents	15
Apart, together: reflections on the COVID-19 pandemic	15
Advisory Board and Contents	14
Current landscape of preclinical models of diabetic cardiomyopathy	14

Subscription and Copyright Information	14
Multiple hERG channel blocking pathways: implications for macromolecules	14
Isoform-selective targeting of PI3K: time to consider new opportunities?	14
Advisory Board and Contents	14
Advisory Board and Contents	14
Fluorescent RNAs: new opportunities for drug discovery	14
Endometriosis: cannabidiol therapy for symptom relief	13
Safety of medicines and vaccines – building next generation capability	13
Subscription and Copyright Information	13
Targeting sialylation to treat central nervous system diseases	13
Reactive chemistry for covalent probe and therapeutic development	13
Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation	13
Advances in spatial mass spectrometry enable in-depth neuropharmacodynamics	13
Recent breakthroughs and future directions in drugging aquaporins	13
Engineering extracellular vesicles for diagnosis and therapy	13
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma	13
Subtyping for pancreatic cancer precision therapy	13
At last: the mitochondrial pyruvate carrier structure revealed!	13
A mechanism for ligand-dependent activation of AHR	13
Advisory Board and Contents	13
Advisory Board and Contents	12
TNIK’s emerging role in cancer, metabolism, and age-related diseases	12
Present and future of microglial pharmacology	12
Subscription and Copyright Information	12
Targeting chromosomal instability and aneuploidy in cancer	12
Nanodelivery of cGAS-STING activators for tumor immunotherapy	12
Advisory Board and Contents	12
Targeting galectin-3 in inflammatory and fibrotic diseases	12
In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target	11
Photoswitchable allosteric and dualsteric ligands in GPCR pharmacology	11
Casimersen for the treatment of Duchenne muscular dystrophy	11
IRAK4: potential therapeutic target for airway disease exacerbations	11
Paving the way for designing drugs targeting TMEM16A	11
Unifying mechanism behind the onset of acquired epilepsy	11
Mutations in muscle-type creatine kinase impact HIV prevention	10
Subscription and Copyright Information	10
Calcitonin/PAC1 receptor splice variants: a blind spot in migraine research	10
Giving ERK a jERK from the endosome	10
Subscription and Copyright Information	10
Repurposing trifluoperazine for glioblastoma treatment	10
Structural snapshot of a β-arrestin-biased receptor	10
Advisory Board and Contents	10
Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads	9
Subscription and Copyright Information	9
A quick guide to networking for scientists	9
Therapeutic targeting of exportin-1 beyond nuclear export	9
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery	9
Copper homeostasis and cuproptosis in cardiovascular disease therapeutics	9
Heterobifunctional small molecules to modulate RNA function	9
Fezolinetant for menopausal hot flashes and night sweats	9
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities	9
Iron metabolism: pathophysiology and pharmacology	9
Current views on N-glycolylneuraminic acid in therapeutic recombinant proteins	8
Cholesterol – the devil you know; ceramide – the devil you don’t	8
Targeting neurological abnormalities in lysosomal storage diseases	8
VMAT structures reveal exciting targets for drug development	8
The structure and function of olfactory receptors	7
The potential of long noncoding RNA therapies	7
Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain	7
Subscription and Copyright Information	7
PPAR agonists for the treatment of neuroinflammatory diseases	7
Emerging paradigms and recent progress in targeting ErbB in cancers	7
ACK1/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics	7
Subscription and Copyright Information	7
Differences in pathogenicity among the mpox virus clades: impact on drug discovery and vaccine development	7
Targeting TRPM channels for cerebral ischemia–reperfusion injury	7
Advances in cell therapy: progress and challenges in hematological and solid tumors	7
Hypothalamic AMPK as a possible target for energy balance-related diseases	6
Data and AI-driven synthetic binding protein discovery	6
Gut-derived brain T cells modulate behavior via IFN-γ	6
PSA inhibitors for contraception: insights from prostate cancer	6
Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment	6
Emerging mechanisms and therapeutics in inflammatory muscle diseases	6
Subscription and Copyright Information	6
Regulation of drug-metabolizing enzymes by sex-related hormones: clinical implications for transgender medicine	6
Targeting Fks1 proteins for novel antifungal drug discovery	6
Some assembly required: a single-RNA vaccine against enterovirus-D68	6
Design and development of glucocorticoid receptor modulators	6
Enhancing oncogenic signaling to kill cancer cells	5
Targeting solute carriers to modulate receptor–ligand interactions	5
Pharmacogenomics in treatment of depression and psychosis: an update	5
Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies	5
Advisory Board and Contents	5
FOXO transcription factors as therapeutic targets in human diseases	5
Chromosome-scale genomes throw light on plant drug biosynthesis	5
Leveraging spatial omics for the development of precision sarcoma treatments	5
Glycine: a long-sought novel ligand for GPR158	5
Advisory Board and Contents	5
Efferocytosis in inflammatory bone disorders	5
Mitochondrial quality control: prime targets for antiviral therapy?	5
A decoy mutant ACE2 designed to reduce COVID-19	5
Subscription and Copyright Information	5
Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity	5
The future of neuroimmunology research for CNS disease therapeutics	5
Emerging approaches for antagonizing the aryl hydrocarbon receptor	5